Sanofi SA (NYSE:SNY) gapped up prior to trading on Wednesday . The stock had previously closed at $44.55, but opened at $45.55. Sanofi shares last traded at $46.61, with a volume of 3,858,900 shares trading hands.
A number of analysts have commented on SNY shares. Morgan Stanley upgraded shares of Sanofi from an “equal” rating to a “weight” rating in a research note on Friday, September 20th. UBS Group upgraded shares of Sanofi from a “neutral” rating to a “buy” rating in a report on Wednesday, August 14th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research note on Monday, October 14th. Argus reiterated a “buy” rating and set a $52.00 price objective (up from $50.00) on shares of Sanofi in a report on Wednesday, November 13th. Finally, Guggenheim raised shares of Sanofi from a “neutral” rating to a “buy” rating in a research report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $50.33.
The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40. The firm has a 50 day moving average price of $46.17 and a 200 day moving average price of $43.93. The stock has a market capitalization of $115.59 billion, a PE ratio of 14.71, a P/E/G ratio of 2.41 and a beta of 0.67.
Sanofi (NYSE:SNY) last announced its earnings results on Thursday, October 31st. The company reported $1.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.96 by $0.11. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The company had revenue of $10.56 billion for the quarter, compared to analysts’ expectations of $10.62 billion. On average, equities analysts forecast that Sanofi SA will post 3.1 earnings per share for the current fiscal year.
In other Sanofi news, major shareholder Sanofi sold 172,904 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $281.15, for a total transaction of $48,611,959.60. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 1.00% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Ibex Wealth Advisors purchased a new stake in Sanofi in the 2nd quarter valued at about $25,000. Heritage Wealth Advisors increased its position in shares of Sanofi by 141.2% during the second quarter. Heritage Wealth Advisors now owns 603 shares of the company’s stock valued at $26,000 after acquiring an additional 353 shares during the last quarter. Prestige Wealth Management Group LLC purchased a new stake in shares of Sanofi during the second quarter valued at approximately $37,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in Sanofi during the third quarter worth $37,000. Finally, Stonebridge Capital Advisors LLC bought a new stake in Sanofi during the second quarter worth $41,000. Institutional investors and hedge funds own 7.04% of the company’s stock.
Sanofi Company Profile (NYSE:SNY)
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Recommended Story: Momentum Indicators
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.